# OnCo record paper-lynch-egfr-activating-mutations-gefitinib-nejm-2004 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-lynch-egfr-activating-mutations-gefitinib-nejm-2004/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-lynch-egfr-activating-mutations-gefitinib-nejm-2004" ;
  schema:name "Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib"@en ;
  schema:description "A drug that worked spectacularly in about one patient in ten and did nothing in the rest. Sequencing the tumours of nine responders found the answer: eight of them had a mutation in the gene the drug targets."@en ;
  schema:url <https://onco.cc/key-papers/paper-lynch-egfr-activating-mutations-gefitinib-nejm-2004/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa040938>, <https://pubmed.ncbi.nlm.nih.gov/15118073/> ;
  onco:tag "lung-evidence" ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa040938> ;
  schema:datePublished "2004"^^xsd:gYear ;
  schema:author "Lynch TJ, Bell DW, Sordella R, et al." ;
  onco:related <https://onco.cc/key-papers/paper-paez-egfr-mutations-gefitinib-science-2004/>, <https://onco.cc/key-papers/paper-mok-ipass-gefitinib-pulmonary-adenocarcinoma-nejm-2009/>, <https://onco.cc/key-papers/paper-kobayashi-egfr-t790m-gefitinib-resistance-nejm-2005/>, <https://onco.cc/roadmaps/targeted-therapy-roadmap/> ;
  onco:cancers <https://onco.cc/cancers/lung-cancer/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/egfr-mutant-nsclc/>, <https://onco.cc/cancers/lung-adenocarcinoma/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/>, <https://onco.cc/fronts/diagnostics/> ;
  onco:technologies <https://onco.cc/terms/ngs/> ;
  onco:targets <https://onco.cc/targets/egfr/> ;
  onco:drugs <https://onco.cc/drugs/gefitinib/>, <https://onco.cc/drugs/erlotinib/> ;
  onco:institutions <https://onco.cc/institutions/mgh/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/pi3k-akt-mtor/> ;
  onco:terms <https://onco.cc/terms/driver-mutation/>, <https://onco.cc/terms/oncogene-addiction/> ;
  onco:people <https://onco.cc/people/thomas-lynch/>, <https://onco.cc/people/lecia-sequist/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-biomarker-validation/>, <https://onco.cc/bottlenecks/b-undruggable-targets/>, <https://onco.cc/bottlenecks/b-translational-valley/> ;
  onco:journals <https://onco.cc/journals/nejm/> .
